#ACR 2024 BEST Abstracts from Day 3

Jack Cush, MD

Nov 18, 2024 5:13 pm

Lots of lupus research and the New ACR Guidelines on Lupus Nephritis management were presented today. These and other highlights as featured on our Twitter (X) feed from ACR24 in Washington, DC.

Phase 2 DAHLIA study in Sjogrens

Anti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging results

clinESSDAI significantly better at wk24, notably met QOL domains as well

Finally getting good news in SjS!#ACR24 @RheumNow #ACRbest Abst#2527 pic.twitter.com/e3uQmqJZ1o
— Mike Putman (@EBRheum) November 18, 2024

A#2527 DAHLIAS, P2
Nipocalimab: Anti-FcRn Ab in Ro+ SjD
IV 5 or 15 mg/kg
Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002
Improv dryness, fatigue, pain
Better unstim salivary flow
Best response in higher Ab titer pts
Safety data good#ACRBest #ACR24 @RheumNow pic.twitter.com/O7zahPul66
— Eric Dein (@ericdeinmd) November 18, 2024

Selective TYK2i zasocitinib, results of Phase 2 DBRCT

Dose dependent improvements in various PsA outcomes; NNT~5 for DAS28 remission, NNT~20 for PASDAS

Hard to compare to current agents, somewhere between JAKs (woot!) & "apremlist zone" 🫣#ACR24 @RheumNow Abstr#2584 #ACRbest pic.twitter.com/t0y6C618ll
— Mike Putman (@EBRheum) November 18, 2024

#2259
💊 Anti-Obesity Meds in RA

📊 152 RA patients on semaglutide/tirzepatide

🔑 Findings
💥Significant ⬇️weight, BMI, ESR, CRP, lipids, pain VAS
💥Improved CVD risk

⛔ 15% GI side effects, 27% discontinued

🔎Study of impact on RA outcomes needed#ACR24 @RheumNow #ACRBest pic.twitter.com/6LCTZl5173
— Caoilfhionn Connolly (@CaoilfhionnMD) November 18, 2024

Abst#1493 complete renal response (< 0.5 g/g w/< 10 mg/day pred); renal remission (UPCR < 0.3 g/g w/< 5 mg/day pred). 60 LN pts followed 3 yrs: 40% CRR & 19% RR. Pts not in CRR/RR had⬇️eGFR w/more decline in eGFR over time. No difference b/t CRR/ RR @rheumnow #ACRbest #ACR24
— TheDaoIndex (@KDAO2011) November 18, 2024

📢Late-breaking #2003

🔑 Cappelli et al @jhrheumatology finds hip OA is NOT a significant risk factor for #ICI-IA

🔴#ICI-IA linked to lower mortality#ACR24 #ACRBest @RheumNow
— Caoilfhionn Connolly (@CaoilfhionnMD) November 18, 2024

Always looking for cancer/CV signals from JAKi in big observational datasets w extensive JAKi use

nationwide 🇯🇵 claims data
RA pts n=52k (JAKi n=4.3k)
Cancer with JAKi vs TNFi: aHR 2.2
(esp lung, lymphoma)

This is a problem. Watch these data.#ACR24 ABST1336 @RheumNow #ACRBest pic.twitter.com/vsnT46De6T
— David Liew (@drdavidliew) November 18, 2024